Proteins and Peptides

17 Dec 2020 Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
16 Dec 2020 Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes
16 Dec 2020 Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide
16 Dec 2020 Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
11 Dec 2020 Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
10 Dec 2020 Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
09 Dec 2020 Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
08 Dec 2020 Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
08 Dec 2020 Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
07 Dec 2020 ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
06 Dec 2020 Bioniz Announces Positive Clinical Data of BNZ-1, First Anti-Cytokine Therapy to Demonstrate Efficacy in Treating Refractory Cutaneous T-Cell Lymphoma
06 Dec 2020 FDA approves Saxenda® for the treatment of obesity in adolescents aged 12–17
04 Dec 2020 Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
04 Dec 2020 APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01
02 Dec 2020 Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
28 Nov 2020 Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
23 Nov 2020 ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
23 Nov 2020 Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin® Therapeutic Candidate MP0420
18 Nov 2020 FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
17 Nov 2020 Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
17 Nov 2020 Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
17 Nov 2020 Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
16 Nov 2020 Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
16 Nov 2020 Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH
15 Nov 2020 Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up